Media ReleasesCircadian

View All Circadian News


Healthscope commences clinical validation study of Circadian’s Cancer Diagnostic

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announced today that Healthscope Limited, its licensee and development partner for a novel diagnostic technology for “Cancers of Unknown Primary” (CUP), has completed development and validation of a commercial test candidate and is commencing a “beta test” trial amongst Australian oncologists as the final development stage before making the test commercially available.


For further information please download PDF below:

Download this document